Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Acquired by Natixis Advisors LLC

Natixis Advisors LLC increased its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 14.9% during the 3rd quarter, HoldingsChannel reports. The fund owned 39,318 shares of the specialty pharmaceutical company’s stock after acquiring an additional 5,113 shares during the quarter. Natixis Advisors LLC’s holdings in Supernus Pharmaceuticals were worth $1,226,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of SUPN. Armistice Capital LLC boosted its holdings in Supernus Pharmaceuticals by 47.6% in the 2nd quarter. Armistice Capital LLC now owns 5,272,000 shares of the specialty pharmaceutical company’s stock valued at $141,026,000 after purchasing an additional 1,700,000 shares during the last quarter. Pacer Advisors Inc. raised its position in shares of Supernus Pharmaceuticals by 100,186.3% during the 2nd quarter. Pacer Advisors Inc. now owns 1,349,854 shares of the specialty pharmaceutical company’s stock valued at $36,109,000 after buying an additional 1,348,508 shares during the period. American Century Companies Inc. grew its position in Supernus Pharmaceuticals by 369.1% in the second quarter. American Century Companies Inc. now owns 501,658 shares of the specialty pharmaceutical company’s stock worth $13,419,000 after acquiring an additional 394,728 shares during the period. Renaissance Technologies LLC increased its stake in Supernus Pharmaceuticals by 26.4% during the second quarter. Renaissance Technologies LLC now owns 1,685,122 shares of the specialty pharmaceutical company’s stock worth $45,077,000 after acquiring an additional 351,900 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in Supernus Pharmaceuticals by 12.1% in the second quarter. Dimensional Fund Advisors LP now owns 2,866,887 shares of the specialty pharmaceutical company’s stock valued at $76,690,000 after purchasing an additional 309,966 shares during the period.

Supernus Pharmaceuticals Stock Performance

Shares of NASDAQ SUPN opened at $36.14 on Wednesday. The stock’s 50-day simple moving average is $33.81 and its 200-day simple moving average is $31.14. The firm has a market capitalization of $2.00 billion, a PE ratio of 33.78 and a beta of 0.86. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $25.53 and a fifty-two week high of $39.37.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.25. The company had revenue of $175.70 million during the quarter, compared to the consensus estimate of $157.35 million. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. Supernus Pharmaceuticals’s revenue for the quarter was up 14.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.29) earnings per share. On average, sell-side analysts forecast that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current fiscal year.

Analyst Ratings Changes

SUPN has been the subject of several research analyst reports. StockNews.com raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Cowen reiterated a “buy” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Finally, Piper Sandler reissued a “neutral” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th.

Insider Activity

In other news, SVP Frank Mottola sold 15,000 shares of the stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $36.98, for a total value of $554,700.00. Following the completion of the transaction, the senior vice president now owns 8,200 shares in the company, valued at $303,236. This trade represents a 64.66 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Jack A. Khattar sold 125,000 shares of the firm’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $36.68, for a total transaction of $4,585,000.00. Following the completion of the sale, the chief executive officer now owns 926,172 shares of the company’s stock, valued at $33,971,988.96. This trade represents a 11.89 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 154,213 shares of company stock valued at $5,660,180. Company insiders own 9.30% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.